Difference between revisions of "High-grade glioma, pediatric"
Jump to navigation
Jump to search
m |
|||
| Line 11: | Line 11: | ||
|} | |} | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
| − | |||
=Adjuvant therapy= | =Adjuvant therapy= | ||
==Lomustine, Vincristine, Prednisone {{#subobject:f7dcb5|Regimen=1}}== | ==Lomustine, Vincristine, Prednisone {{#subobject:f7dcb5|Regimen=1}}== | ||
| − | + | <div class="toccolours" style="background-color:#eeeeee"> | |
===Regimen {{#subobject:251b74|Variant=1}}=== | ===Regimen {{#subobject:251b74|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 100%; text-align:center;" | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
| Line 30: | Line 29: | ||
|- | |- | ||
|} | |} | ||
| + | <div class="toccolours" style="background-color:#cbd5e8"> | ||
====Preceding treatment==== | ====Preceding treatment==== | ||
| − | |||
*[[Surgery#CNS_cancer_surgery|Surgery]], then [[#Vincristine_.26_RT_88|Vincristine & RT]] | *[[Surgery#CNS_cancer_surgery|Surgery]], then [[#Vincristine_.26_RT_88|Vincristine & RT]] | ||
| − | + | </div> | |
| + | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
| − | |||
*[[Lomustine (CCNU)]] | *[[Lomustine (CCNU)]] | ||
*[[Vincristine (Oncovin)]] | *[[Vincristine (Oncovin)]] | ||
====Glucocorticoid therapy==== | ====Glucocorticoid therapy==== | ||
*[[Prednisone (Sterapred)]] | *[[Prednisone (Sterapred)]] | ||
| − | + | </div></div> | |
===References=== | ===References=== | ||
| − | |||
#'''CCG-945:''' Finlay JL, Boyett JM, Yates AJ, Wisoff JH, Milstein JM, Geyer JR, Bertolone SJ, McGuire P, Cherlow JM, Tefft M, Turski PA, Wara WM, Edwards M, Sutton LN, Berger MS, Epstein F, Ayers G, Allen JC, Packer RJ; Children's Cancer Group. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. J Clin Oncol. 1995 Jan;13(1):112-23. [https://doi.org/10.1200/JCO.1995.13.1.112 link to original article] [https://pubmed.ncbi.nlm.nih.gov/7799011 PubMed] | #'''CCG-945:''' Finlay JL, Boyett JM, Yates AJ, Wisoff JH, Milstein JM, Geyer JR, Bertolone SJ, McGuire P, Cherlow JM, Tefft M, Turski PA, Wara WM, Edwards M, Sutton LN, Berger MS, Epstein F, Ayers G, Allen JC, Packer RJ; Children's Cancer Group. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. J Clin Oncol. 1995 Jan;13(1):112-23. [https://doi.org/10.1200/JCO.1995.13.1.112 link to original article] [https://pubmed.ncbi.nlm.nih.gov/7799011 PubMed] | ||
| − | |||
==Temozolomide & RT {{#subobject:5fe805|Regimen=1}}== | ==Temozolomide & RT {{#subobject:5fe805|Regimen=1}}== | ||
| − | |||
Temozolomide & RT: Temozolomide & '''<u>R</u>'''adiation '''<u>T</u>'''herapy | Temozolomide & RT: Temozolomide & '''<u>R</u>'''adiation '''<u>T</u>'''herapy | ||
| + | <div class="toccolours" style="background-color:#eeeeee"> | ||
===Regimen {{#subobject:2a87ef|Variant=1}}=== | ===Regimen {{#subobject:2a87ef|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 100%; text-align:center;" | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
| Line 63: | Line 60: | ||
|- | |- | ||
|} | |} | ||
| + | <div class="toccolours" style="background-color:#cbd5e8"> | ||
====Preceding treatment==== | ====Preceding treatment==== | ||
| − | |||
*[[Surgery#CNS_cancer_surgery|Surgical biopsy, partial resection, or total resection]] | *[[Surgery#CNS_cancer_surgery|Surgical biopsy, partial resection, or total resection]] | ||
| − | + | </div> | |
| + | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
| − | |||
*[[Temozolomide (Temodar)]] as follows: | *[[Temozolomide (Temodar)]] as follows: | ||
**Cycle 1: 75 mg/m<sup>2</sup> PO or IV once per day | **Cycle 1: 75 mg/m<sup>2</sup> PO or IV once per day | ||
**Cycles 2 to 13: 150 to 200 mg/m<sup>2</sup> PO once per day on days 1 to 5 | **Cycles 2 to 13: 150 to 200 mg/m<sup>2</sup> PO once per day on days 1 to 5 | ||
| − | |||
====Radiotherapy==== | ====Radiotherapy==== | ||
| − | |||
*Concurrent [[External_beam_radiotherapy|radiation therapy]] as follows: | *Concurrent [[External_beam_radiotherapy|radiation therapy]] as follows: | ||
**Cycle 1: 1.8 Gy fractions x 30 fractions, for a total dose of 54 Gy | **Cycle 1: 1.8 Gy fractions x 30 fractions, for a total dose of 54 Gy | ||
| − | |||
'''6-week course, then 4-week break, then 28-day cycle for up to 12 cycles''' | '''6-week course, then 4-week break, then 28-day cycle for up to 12 cycles''' | ||
| − | + | </div></div> | |
===References=== | ===References=== | ||
#'''HERBY:''' Grill J, Massimino M, Bouffet E, Azizi AA, McCowage G, Cañete A, Saran F, Le Deley MC, Varlet P, Morgan PS, Jaspan T, Jones C, Giangaspero F, Smith H, Garcia J, Elze MC, Rousseau RF, Abrey L, Hargrave D, Vassal G. Phase II, open-label, randomized, multicenter trial (HERBY) of bevacizumab in pediatric patients with newly diagnosed high-grade glioma. J Clin Oncol. 2018 Apr 1;36(10):951-958. Epub 2018 Feb 7. [https://doi.org/10.1200/JCO.2017.76.0611 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/29412784 PubMed] NCT01390948 | #'''HERBY:''' Grill J, Massimino M, Bouffet E, Azizi AA, McCowage G, Cañete A, Saran F, Le Deley MC, Varlet P, Morgan PS, Jaspan T, Jones C, Giangaspero F, Smith H, Garcia J, Elze MC, Rousseau RF, Abrey L, Hargrave D, Vassal G. Phase II, open-label, randomized, multicenter trial (HERBY) of bevacizumab in pediatric patients with newly diagnosed high-grade glioma. J Clin Oncol. 2018 Apr 1;36(10):951-958. Epub 2018 Feb 7. [https://doi.org/10.1200/JCO.2017.76.0611 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/29412784 PubMed] NCT01390948 | ||
| − | |||
=Recurrent disease, non-curative therapy, non-randomized or retrospective data= | =Recurrent disease, non-curative therapy, non-randomized or retrospective data= | ||
| − | |||
==Temozolomide monotherapy {{#subobject:e73a18|Regimen=1}}== | ==Temozolomide monotherapy {{#subobject:e73a18|Regimen=1}}== | ||
| − | + | <div class="toccolours" style="background-color:#eeeeee"> | |
===Regimen variant #1, no radiation history {{#subobject:f06af9|Variant=1}}=== | ===Regimen variant #1, no radiation history {{#subobject:f06af9|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 60%; text-align:center;" | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
| Line 98: | Line 90: | ||
|- | |- | ||
|} | |} | ||
| + | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
| − | |||
*[[Temozolomide (Temodar)]] 150 to 200 mg/m<sup>2</sup> PO once per day on days 1 to 5 | *[[Temozolomide (Temodar)]] 150 to 200 mg/m<sup>2</sup> PO once per day on days 1 to 5 | ||
**Patients who previously received craniospinal irradiation (CSI) instead received 180 mg/m<sup>2</sup> PO once per day on days 1 to 5 | **Patients who previously received craniospinal irradiation (CSI) instead received 180 mg/m<sup>2</sup> PO once per day on days 1 to 5 | ||
| − | |||
'''28-day cycle for up to 11 cycles''' | '''28-day cycle for up to 11 cycles''' | ||
| − | + | </div></div><br> | |
| + | <div class="toccolours" style="background-color:#eeeeee"> | ||
===Regimen variant #2, previous craniospinal irradiation (CSI) {{#subobject:f06tf5|Variant=1}}=== | ===Regimen variant #2, previous craniospinal irradiation (CSI) {{#subobject:f06tf5|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 60%; text-align:center;" | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
| Line 116: | Line 108: | ||
|- | |- | ||
|} | |} | ||
| + | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
| − | |||
*[[Temozolomide (Temodar)]] 180 mg/m<sup>2</sup> PO once per day on days 1 to 5 | *[[Temozolomide (Temodar)]] 180 mg/m<sup>2</sup> PO once per day on days 1 to 5 | ||
| − | |||
'''28-day cycle for up to 11 cycles''' | '''28-day cycle for up to 11 cycles''' | ||
| − | + | </div></div> | |
===References=== | ===References=== | ||
#Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok N, Mazewski C, Sato J, Reaman GH; Children's Oncology Group. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer. 2007 Oct 1;110(7):1542-50. [https://doi.org/10.1002/cncr.22961 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/17705175 PubMed] | #Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok N, Mazewski C, Sato J, Reaman GH; Children's Oncology Group. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer. 2007 Oct 1;110(7):1542-50. [https://doi.org/10.1002/cncr.22961 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/17705175 PubMed] | ||
| − | |||
=Investigational agents= | =Investigational agents= | ||
*[[G207]] | *[[G207]] | ||
| − | |||
[[Category:High-grade glioma regimens]] | [[Category:High-grade glioma regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:High-grade gliomas]] | [[Category:High-grade gliomas]] | ||
[[Category:Pediatric neurologic neoplasms]] | [[Category:Pediatric neurologic neoplasms]] | ||
Revision as of 00:11, 1 March 2023
Section editor transclusions This page contains studies that are specific to pediatric populations. For the more general high-grade glioma category page, follow this link.
4 regimens on this page
5 variants on this page
|
Adjuvant therapy
Lomustine, Vincristine, Prednisone
Regimen
| Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Finlay et al. 1995 | 1985-1990 | Phase 3 (C) | 8-drug regimen | Did not meet primary endpoint of OS |
Preceding treatment
- Surgery, then Vincristine & RT
References
- CCG-945: Finlay JL, Boyett JM, Yates AJ, Wisoff JH, Milstein JM, Geyer JR, Bertolone SJ, McGuire P, Cherlow JM, Tefft M, Turski PA, Wara WM, Edwards M, Sutton LN, Berger MS, Epstein F, Ayers G, Allen JC, Packer RJ; Children's Cancer Group. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. J Clin Oncol. 1995 Jan;13(1):112-23. link to original article PubMed
Temozolomide & RT
Temozolomide & RT: Temozolomide & Radiation Therapy
Regimen
| Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Grill et al. 2018 (HERBY) | 2011-2015 | Randomized Phase 2 (C) | Temozolomide, Bevacizumab, RT | Did not meet primary endpoint of EFS |
Preceding treatment
Chemotherapy
- Temozolomide (Temodar) as follows:
- Cycle 1: 75 mg/m2 PO or IV once per day
- Cycles 2 to 13: 150 to 200 mg/m2 PO once per day on days 1 to 5
Radiotherapy
- Concurrent radiation therapy as follows:
- Cycle 1: 1.8 Gy fractions x 30 fractions, for a total dose of 54 Gy
6-week course, then 4-week break, then 28-day cycle for up to 12 cycles
References
- HERBY: Grill J, Massimino M, Bouffet E, Azizi AA, McCowage G, Cañete A, Saran F, Le Deley MC, Varlet P, Morgan PS, Jaspan T, Jones C, Giangaspero F, Smith H, Garcia J, Elze MC, Rousseau RF, Abrey L, Hargrave D, Vassal G. Phase II, open-label, randomized, multicenter trial (HERBY) of bevacizumab in pediatric patients with newly diagnosed high-grade glioma. J Clin Oncol. 2018 Apr 1;36(10):951-958. Epub 2018 Feb 7. link to original article contains dosing details in manuscript PubMed NCT01390948
Recurrent disease, non-curative therapy, non-randomized or retrospective data
Temozolomide monotherapy
Regimen variant #1, no radiation history
| Study | Years of enrollment | Evidence |
|---|---|---|
| Nicholson et al. 2007 | 1998-1999 | Non-randomized |
Chemotherapy
- Temozolomide (Temodar) 150 to 200 mg/m2 PO once per day on days 1 to 5
- Patients who previously received craniospinal irradiation (CSI) instead received 180 mg/m2 PO once per day on days 1 to 5
28-day cycle for up to 11 cycles
Regimen variant #2, previous craniospinal irradiation (CSI)
| Study | Years of enrollment | Evidence |
|---|---|---|
| Nicholson et al. 2007 | 1998-1999 | Non-randomized |
Chemotherapy
- Temozolomide (Temodar) 180 mg/m2 PO once per day on days 1 to 5
28-day cycle for up to 11 cycles
References
- Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok N, Mazewski C, Sato J, Reaman GH; Children's Oncology Group. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer. 2007 Oct 1;110(7):1542-50. link to original article contains dosing details in manuscript PubMed